Laurens J Ceulemans

Prof. Dr. Laurens J Ceulemans

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2009 in Journal of Hand Surgery (European Volume)
Verified
Journal Article
Closed access
PDF file
JMJ. S. Mulford
J. S. Mulford
LCLaurens J Ceulemans
Laurens J Ceulemans
DND. Nam
D. Nam
TAT. S. Axelrod
T. S. Axelrod
Proximal row carpectomy (PRC) and scaphoid excision with four-corner fusion (4CF) are common motion-preserving, salvage procedures for the treatment of wrists with scaphoid nonunion (SNAC) or scapholunate advanced collapse (SLAC). A systematic review was undertaken to clarify controversies regarding which of these procedures has the better outcome. We collated 52 articles that examine outcomes for SNAC or SLAC patients undergoing PRC or 4CF. Although the lack of unbiased trials must be acknowledged, this systematic review confirms that both procedures give improvements in pain and subjective outcome measures for patients with symptomatic and appropriately staged SLAC or SNAC wrists. PRC may provide better postoperative range of movement and lacks the potential complications specific to 4CF (nonunion, hardware issues and dorsal impingement). However, the risk of subsequent osteoarthritis is significantly higher in PRC patients despite the majority being asymptomatic at the time of review. Grip strength, pain relief and subjective outcomes are similar in both treatment groups.

1 May 2020 in Transplantation
Verified
Journal Article
Closed access
SKStuart S. Kaufman
Stuart S. Kaufman
YAYaron Avitzur
Yaron Avitzur
SBSue V. Beath
Sue V. Beath
LCLaurens J Ceulemans
Laurens J Ceulemans
GGGabriel E. Gondolesi
Gabriel E. Gondolesi
LPLoris Pironi
Loris Pironi
In 2001, a Statement was published that described indications for intestinal transplantation in patients with intestinal failure expected to require parenteral nutrition indefinitely. Since 2001, advances in the management of intestinal failure including transplantation and patient survival, both on extended parenteral nutrition and after transplantation, have improved, leading to a reduction in the number of intestinal transplants worldwide from a peak of 270 per year in 2008 to 149 per year in 2017. These changes suggest that the original 2001 Statement requires reassessment. All patients with permanent intestinal failure should be managed by dedicated multidisciplinary intestinal rehabilitation teams. Under care of these teams, patients should be considered for intestinal transplantation in the event of progressive intestinal failure–associated liver disease, progressive loss of central vein access, and repeated life-threatening central venous catheter–associated infections requiring critical care. Additional indications for transplantation include large desmoid tumors and other intra-abdominal tumors with reasonable expectation of posttransplant cure, extensive mesenteric vein thrombosis and intestinal infarction, total intestinal aganglionosis, and nonrecoverable congenital secretory diarrhea. Quality of life typically improves after successful intestinal transplantation and may support the decision to proceed with transplantation when other indications are present. However, the requirement for life-long immunosuppression and its associated side effects preclude intestinal transplantation if motivated only by an expectation of improved quality of life. Increasing experience with intestinal transplantation and critical appraisal of transplant outcomes including graft survival and patient quality of life together with potential advances in immunosuppression can be expected to influence transplant practices in the future.

1 October 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
JDJean-Paul Decuypere
Jean-Paul Decuypere
LCLaurens J Ceulemans
Laurens J Ceulemans
PAPatrizia Agostinis
Patrizia Agostinis
DMDiethard Monbaliu
Diethard Monbaliu
MNMaarten Naesens
Maarten Naesens
IJIna Jochmans
Ina Jochmans

1 February 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KLKathrin I. Liszt
Kathrin I. Liszt
QWQiaoling Wang
Qiaoling Wang
MFMona Farhadipour
Mona Farhadipour
ASAnneleen Segers
Anneleen Segers
TTTheo Thijs
Theo Thijs
IDInge Depoortere
Inge Depoortere
Bitter taste receptors (taste 2 receptors, TAS2Rs) serve as warning sensors in the lingual system against the ingestion of potentially poisonous food. Here, we investigated the functional role of TAS2Rs in the human gut and focused on their potential to trigger an additional host defense pathway in the intestine. Human jejunal crypts, especially those from individuals with obesity, responded to bitter agonists by inducing the release of antimicrobial peptides (α-defensin 5 and regenerating islet–derived protein 3 α [REG3A]) but also regulated the expression of other innate immune factors (mucins, chemokines) that affected E. coli growth. We found that the effect of aloin on E. coli growth and on the release of the mucus glycoprotein CLCA1, identified via proteomics, was affected by TAS2R43 deletion polymorphisms and thus confirmed a role for TAS2R43. RNA-Seq revealed that denatonium benzoate induced an NRF2-mediated nutrient stress response and an unfolded protein response that increased the expression of the mitokine GDF15 but also ADM2 and LDLR, genes that are involved in anorectic signaling and lipid homeostasis. In conclusion, TAS2Rs in the intestine constitute a promising target for treating diseases that involve disturbances in the innate immune system and body weight control. TAS2R polymorphisms may be valuable genetic markers to predict therapeutic responses.

1 June 2013 in Current Opinion in Organ Transplantation
Verified
Journal Article
Closed access
KLKaatje Lenaerts
Kaatje Lenaerts
LCLaurens J Ceulemans
Laurens J Ceulemans
IHInca H.R. Hundscheid
Inca H.R. Hundscheid
JGJoep Grootjans
Joep Grootjans
CDCornelis H.C. Dejong
Cornelis H.C. Dejong
SDSteven W.M. Olde Damink
Steven W.M. Olde Damink
Ischemia-reperfusion injury is inevitable during intestinal transplantation and can negatively affect the transplant outcome. Here, an overview is provided of the recent advances in the pathophysiological mechanisms of intestinal ischemia-reperfusion injury and how this may impact graft survival. The intestine hosts a wide range of microorganisms and its mucosa is heavily populated by immune cells. Intestinal ischemia-reperfusion results in the disruption of the epithelial lining, affecting also protective Paneth cells (antimicrobials) and goblet cells (mucus), and creates a more hostile intraluminal microenvironment. Consequently, both damage-associated molecular patterns as well as pathogen-associated molecular patterns are released from injured tissue and exogenous microorganisms, respectively. These 'danger' signals may synergistically activate the innate immune system. Exaggerated innate immune responses, involving neutrophils, mast cells, platelets, dendritic cells, as well as Toll-like receptors and complement proteins, may shape the adaptive T-cell response, thereby triggering the destructive alloimmune response toward the graft and resulting in transplant rejection. Innate immune activation as a consequence of ischemia-reperfusion injury may compromise engraftment of the intestine. More dedicated research is required to further establish this concept in man and to design more effective therapeutic strategies to better tolerize intestinal grafts.

1 August 2021 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
LCLaurens J Ceulemans
Laurens J Ceulemans
MKMona Khan
Mona Khan
SYSeung-Jun Yoo
Seung-Jun Yoo
BZBolek Zapiec
Bolek Zapiec
LGLaura Van Gerven
Laura Van Gerven
PMPeter Mombaerts
Peter Mombaerts